A groundbreaking study reveals the environmental and public health advantages of reed wetlands for sludge treatment, demonstrating their potential as an eco-friendly alternative to traditional wastewater management systems.

Glaucoma, the leading cause of blindness, is often marked by loss of retinal ganglion cells (RGCs). Necroptosis, a form of programmed cell death, plays a critical role in RGC death, mediated by receptor-interacting protein kinase 3 (RIPK3). A team of scientists from China leveraged advanced artificial intelligence (AI) technologies to identify RIPK3 inhibitors, including the compound HG9-91-01, which demonstrated neuroprotective effects. This AI-driven approach holds promise for developing novel therapeutic strategies for acute glaucoma.

CAMBRIDGE, Mass., January 2, 2025 — Insilico Medicine (‘Insilico’), a clinical-stage generative artificial intelligence (AI)-driven drug discovery and development company, today announced the nomination of ISM1745, a potentially best-in-class MTA cooperative PRMT5 inhibitor with AI-powered novel scaffold, as preclinical candidate (PCC) for the treatment of MTAP-deleted cancers. Based on de novo design results of Chemistry42, ISM1745 marks the fifth PCC nomination achieved by the Insilico team in the year of 2024, bringing the total number since 2021 to 22.